$34.8M
1 filing since 2025 · latest Equity filed
Instylla is a Bedford, Massachusetts medical device company founded in 2017 that develops novel resorbable liquid embolic agents for interventional radiology. Its lead product, the Embrace Hydrogel Embolic System, has received FDA premarket approval for hypervascular tumor embolization. The company's initial clinical focus is interventional oncology, with additional work on peripheral vascular embolization and hemostasis. It is privately held and venture-backed.
What sets it apart
A hydrogel-based liquid embolic that delivers controlled, targeted and persistent embolization while being resorbable, rather than relying on permanent particle or coil embolics.
An FDA-approved hydrogel liquid embolic system used by interventional radiologists to occlude blood flow to hypervascular tumors.
